Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor, exerts remarkable effects against EGFR T790M resistance mutation-positive non-small cell lung cancer. Identifying T790M mutation by re-biopsy is essential before prescribing osimertinib. Tissue bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Keigo, Naoki, Katsuhiko, Manabe, Tadashi, Masuzawa, Keita, Hasegawa, Hanako, Yasuda, Hiroyuki, Kawada, Ichiro, Soejima, Kenzo, Betsuyaku, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995408/
https://www.ncbi.nlm.nih.gov/pubmed/29922072
http://dx.doi.org/10.2147/OTT.S161745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995408/
https://www.ncbi.nlm.nih.gov/pubmed/29922072
http://dx.doi.org/10.2147/OTT.S161745

Ejemplares similares